Skip to main content
WhiteOak Capital Mutual Fund logo

WhiteOak Capital Pharma and Healthcare Fund

WhiteOak Capital Mutual FundDirectOpen-endedSectoral/ ThematicRiskometer: Very High Risk

NAV

17.46

as of 21 Aug 2026

WhiteOak Capital Pharma and Healthcare Fund is an open-ended Sectoral/ Thematic scheme from WhiteOak Capital Mutual Fund managing ₹741 crore (as of 30 Jun 2026). Its Direct-plan NAV is ₹17.46 as of 21 Aug 2026. The expense ratio is 0.6% a year. Managed by Piyush Baranwal. This page is factual data only — it carries no rating and no recommendation.

Key facts

Expense ratio
0.6% / yr
as of 30 Jun 2026
Fund size
₹741 crore
as of 30 Jun 2026
Exit load
None
SIP available
Yes
Launched
6 Feb 2024
ISIN
INF03VN01886

₹100 invested, fund vs category

The category line is the average of the funds in this category, built from NYVO’s own NAV data.

Rebased to 100data to 20 Aug 2026Benchmark: Nifty 500 Healthcare TRI

Feb 2024Aug 2026
Growth of ₹100, WhiteOak Capital Pharma and Healthcare Fund versus Sectoral/ Thematic average.

WhiteOak Capital Pharma and Healthcare Fund

₹175

+75% on ₹100 over 2.5 yrs

Sectoral/ Thematic average

₹149

+49% on ₹100 over 2.5 yrs

Returns vs category

WindowFundCategory avgGap
3 months11.96%
6 months22.35%
1 year21.10%

No category average is available for this fund. Short windows are noise; the 3 and 5-year rows are the record. Past returns do not predict future returns.

Distance below its own peak

Every dip below 0 is the fund trading under a previous high — how deep and for how long is what a drawdown feels like.

Right now

-0.6% below peak

Feb 2024Deepest: -14.4%Aug 2026

Where the money actually is

Equity

99.0%

Cash

1.0%

Whole-portfolio split, as of 30 Jun 2026.

What it owns

67 positions · top 10 = 45.2%

Market-cap mix

Large 20.7%Mid 24.4%Small 49.5%Other 5.4%

as of 30 Jun 2026

Holdings by sector

  • Healthcare(9 in top 10)85.6%
    • Sun Pharmaceuticals Industries Ltd8.66%
    • J.B. Chemicals & Pharmaceuticals Ltd6.94%
    • Laurus Labs Ltd4.61%
    • Apollo Hospitals Enterprise Ltd4.59%
    • Max Healthcare Institute Ltd Ordinary Shares4.30%
    • Fortis Healthcare Ltd3.62%
    • Krishna Institute of Medical Sciences Ltd3.30%
    • Cipla Ltd3.25%
    • Sai Life Sciences Ltd3.22%
  • Basic Materials6.5%

Sectors marked ▶ expand to show this fund’s top-10 holdings in that sector. Holdings as of 30 Jun 2026. Portfolio turnover 321.4% a year.

Other top holdings

  • Clearing Corporation Of India Ltd4.58%

Exposure figures are gross: funds that use derivatives (arbitrage, hedged books) hold offsetting positions, so concentration and turnover can read above 100%.

The businesses it owns

P/E (trailing)
44.5
P/B
6.8
Dividend yield
0.5%
Net margin
15.4%
Earnings growth
15.3%
Avg market cap
₹44,305 crore

Money in, money out

Net flow, 12 months
+276 cr
Net flow, 3 months
+75 cr

as of 30 Jun 2026. Flows follow performance more than they predict it.

Quick answers

What is the NAV of WhiteOak Capital Pharma and Healthcare Fund?
₹17.46 per unit as of 21 Aug 2026 (Direct plan, growth). NAV is declared daily on working days.
What is the expense ratio of WhiteOak Capital Pharma and Healthcare Fund?
0.6% a year for the Direct plan, as of 30 Jun 2026.
How large is WhiteOak Capital Pharma and Healthcare Fund?
₹741 crore under management as of 30 Jun 2026, in the Sectoral/ Thematic category.
How risky is WhiteOak Capital Pharma and Healthcare Fund?
Its SEBI Riskometer reading is "Very High Risk". One sector, one story. The most-launched shelf on the map, by far.
Who manages WhiteOak Capital Pharma and Healthcare Fund?
Piyush Baranwal, managing this fund for 2.5 years.

Where this fund sits

Other Sectoral/ Thematic funds

Data: NYVO research systems; each block above states its own as-of date, and blocks with no data for this fund are omitted rather than estimated. NAV updates daily on working days. The benchmark (Nifty 500 Healthcare TRI) is named for reference only; its values are licensed and never shown. This page is factual information about one scheme. It is not investment advice, not a recommendation, and it carries no rating of any kind. Past performance does not predict future returns. Mutual fund investments are subject to market risks; read all scheme related documents carefully.